UPDATE 19/06/2025
Primary Care Prescribing of Mounjaro for Obesity
You may hear in the news that from 23 June 2025 patients in Somerset will be eligible for tirzepatide (Mounjaro®) for the management of obesity, where a clinician considers it an appropriate treatment and ONLY if they have four or more of the following weight related health problems, as well as BMI of 40 and over:
Those accessing the drug will also be required to participate in a structured wraparound care support package focused on good nutrition for health and for increasing physical activity. This support is designed to help people get the most out of their treatment and enhance their ability to achieve and maintain healthy weight loss.
We respectfully ask that due to limited resources in general practice, please avoid contacting the practice to ask for Mounjaro if you do not qualify for the injections.
Of our practice population of 6132 patients, we have 2 patients eligible at this stage.
We will be actively contacting our eligible patients as there is still very strict criteria to be met.
PRIVATE PATIENTS ON MOUNJARO
This only applies from June 23rd 2025 and after that date, it SHOULD NOT be applied retrospectively to patients who have accessed treatment privately and who’s BMI is now below 40.
Should a privately funding patient still fit the above criteria, 4 or more co-morbidities including latest BMI still >=40, then they may access NHS prescribing ONLY if they consent to and are referred into the Somerset structured wraparound support service.
We will continue to update our patients as and when any further information comes out regarding this.
Dr D Edmonds, Dr G Jones, Dr E Jones